Aim: To examine the role of the Modified Glasgow Prognostic Score (mGPS) and Prognostic Nutritional Index (PNI) as prognostic markers for patients with metastatic breast cancer (MBC).
Patients and methods: We investigated the associations of clinico-pathological factors with time-to-treatment failure (TTF) and overall survival (OS) in 110 patients with MBC treated with eribulin.
Results: C-Reactive protein >1 mg/dl, albumin <3.5 g/dl, mGPS=2, and PNI <40 were significant predictors of shorter TTF in univariate analyses. PNI <40 remained a significant and independent predictor of shorter TTF in multivariate analyses. De novo tumor, visceral metastases, C-reactive protein >1 mg/dl, albumin <3.5 g/dl, mGPS=2, and PNI <40 were significant predictors of poor OS at the univariate level. A PNI <40 was a significant and independent predictor of poor OS in multivariate analyses.
Conclusion: PNI is a reliable predictor of TTF and OS in patients with MBC treated with eribulin.
Keywords: Breast cancer; eribulin; modified Glasgow Prognostic Score; prognostic marker; prognostic nutritional index.
Copyright © 2022, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.